British scientists are running the world's first trial of a vaccine that does not need to be kept refrigerated, reports The Times – an innovation with the potential to be a "global lifesaver". Currently, vaccines must be stored and transported chilled or frozen, which is complex, costly and energy intensive, and so a huge barrier to rolling out vaccine programmes in developing countries. But now UK biotech firm Stablepharma has found a way of converting existing vaccines into versions that are "thermostable" at temperatures up to 40°C.